Philips Enters North American Mammo Market with New System
Given concerns about radiation dose and a call for more comfortable machines, officials at Philips saw an opportunity for a new product in the North American mammography market. Last week Philips introduced their MicroDose Mammography system, which officials said provides a lower dose, less stressful scan.
Given concerns about radiation dose and a call for more comfortable machines, officials at Philips saw an opportunity for a new product in the North American mammography market. Last week Philips introduced their MicroDose Mammography system, which officials said provides a lower dose, less stressful scan.
“The U.S. is in the process of turning over the generation one machines to a purchase cycle, so we believe this is the perfect product” for the market, said Pam Benkert, general manager, women’s healthcare for Philips Healthcare. “We wanted a differentiated offering.”
MicroDose is the only FDA-cleared mammography system to use X-ray photon counting technology. The detector captures almost every photon that travels from the source to the breast to the detector, Benkert explained. There’s very little scatter, which allows for an up to 50 percent dose reduction, she said.
The machine also has curved support and a warm position surface, intended to make it more comfortable for the patient, she said.
The product, she said, is “uniquely suited to the population” in North America.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
